Sawai Group Holdings Co., Ltd. (4887.T)
JPY 2052.5
(2.22%)
JPY 2052.5
(2.22%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 18.88 Billion JPY | 11.2% |
| 2022 | 16.98 Billion JPY | 147.33% |
| 2021 | -35.88 Billion JPY | -292.8% |
| 2020 | 18.61 Billion JPY | -30.12% |
| 2019 | 26.63 Billion JPY | 3.06% |
| 2018 | 25.84 Billion JPY | 16.56% |
| 2017 | 22.17 Billion JPY | -5.02% |
| 2016 | 23.34 Billion JPY | 0.7% |
| 2015 | 23.18 Billion JPY | 12.06% |
| 2014 | 20.68 Billion JPY | 8.37% |
| 2013 | 19.09 Billion JPY | 9.98% |
| 2012 | 17.35 Billion JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 6.1 Billion JPY | 311.1% |
| 2023 FY | 18.88 Billion JPY | 11.2% |
| 2023 Q3 | 6.52 Billion JPY | 7.42% |
| 2023 Q4 | 1.48 Billion JPY | -77.24% |
| 2023 Q1 | 4.6 Billion JPY | 76.7% |
| 2023 Q2 | 6.07 Billion JPY | 32.04% |
| 2022 Q4 | 2.6 Billion JPY | -53.17% |
| 2022 Q3 | 5.56 Billion JPY | 39.18% |
| 2022 Q2 | 3.99 Billion JPY | -17.07% |
| 2022 Q1 | 4.82 Billion JPY | 108.06% |
| 2022 FY | 16.98 Billion JPY | 147.33% |
| 2021 Q4 | -59.82 Billion JPY | -691.44% |
| 2021 Q1 | 8.48 Billion JPY | 426.89% |
| 2021 FY | -35.88 Billion JPY | -292.8% |
| 2021 Q3 | 10.11 Billion JPY | 89.45% |
| 2021 Q2 | 5.33 Billion JPY | -37.06% |
| 2020 Q3 | 8.8 Billion JPY | 23.52% |
| 2020 Q1 | 6.88 Billion JPY | 141.44% |
| 2020 FY | 18.61 Billion JPY | -30.12% |
| 2020 Q4 | 1.61 Billion JPY | -81.72% |
| 2020 Q2 | 7.13 Billion JPY | 3.63% |
| 2019 Q4 | 2.85 Billion JPY | -67.2% |
| 2019 Q3 | 8.69 Billion JPY | 36.44% |
| 2019 Q2 | 6.36 Billion JPY | -28.32% |
| 2019 FY | 26.63 Billion JPY | 3.06% |
| 2019 Q1 | 8.88 Billion JPY | 117.4% |
| 2018 Q2 | 6.44 Billion JPY | -11.94% |
| 2018 Q3 | 8.13 Billion JPY | 26.25% |
| 2018 Q1 | 7.32 Billion JPY | 124.13% |
| 2018 FY | 25.84 Billion JPY | 16.56% |
| 2018 Q4 | 4.08 Billion JPY | -49.78% |
| 2017 FY | 22.17 Billion JPY | -5.02% |
| 2017 Q1 | 5.35 Billion JPY | 97.42% |
| 2017 Q4 | 3.26 Billion JPY | -58.8% |
| 2017 Q3 | 7.92 Billion JPY | 38.0% |
| 2017 Q2 | 5.74 Billion JPY | 7.3% |
| 2016 Q2 | 5.44 Billion JPY | -7.18% |
| 2016 Q4 | 2.71 Billion JPY | -58.37% |
| 2016 Q1 | 5.86 Billion JPY | 52.19% |
| 2016 Q3 | 6.51 Billion JPY | 19.61% |
| 2016 FY | 23.34 Billion JPY | 0.7% |
| 2015 FY | 23.18 Billion JPY | 12.06% |
| 2015 Q4 | 3.85 Billion JPY | -50.09% |
| 2015 Q3 | 7.72 Billion JPY | 46.98% |
| 2015 Q2 | 5.25 Billion JPY | -17.27% |
| 2015 Q1 | 6.35 Billion JPY | 93.07% |
| 2014 Q4 | 3.29 Billion JPY | -54.13% |
| 2014 Q3 | 7.17 Billion JPY | 37.94% |
| 2014 Q2 | 5.2 Billion JPY | 3.46% |
| 2014 Q1 | 5.02 Billion JPY | 140.25% |
| 2014 FY | 20.68 Billion JPY | 8.37% |
| 2013 Q2 | 4.21 Billion JPY | -27.69% |
| 2013 Q1 | 5.83 Billion JPY | 83.31% |
| 2013 Q4 | 2.09 Billion JPY | -69.89% |
| 2013 FY | 19.09 Billion JPY | 9.98% |
| 2013 Q3 | 6.94 Billion JPY | 64.72% |
| 2012 Q4 | 3.18 Billion JPY | -48.15% |
| 2012 Q2 | 3.93 Billion JPY | 0.0% |
| 2012 FY | 17.35 Billion JPY | 0.0% |
| 2012 Q3 | 6.13 Billion JPY | 55.88% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 5.11 Billion JPY | -269.372% |
| Takeda Pharmaceutical Company Limited | 214.07 Billion JPY | 91.178% |
| Sumitomo Pharma Co., Ltd. | -354.19 Billion JPY | 105.332% |
| Shionogi & Co., Ltd. | 171.46 Billion JPY | 88.985% |
| Wakamoto Pharmaceutical Co.,Ltd. | -195.51 Million JPY | 9759.815% |
| Nippon Shinyaku Co., Ltd. | 31.38 Billion JPY | 39.827% |
| Kaken Pharmaceutical Co., Ltd. | 9.51 Billion JPY | -98.528% |
| Eisai Co., Ltd. | 53.4 Billion JPY | 64.638% |
| Morishita Jintan Co., Ltd. | 716 Million JPY | -2537.709% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.16 Billion JPY | -43.434% |
| Mochida Pharmaceutical Co., Ltd. | 5.8 Billion JPY | -225.452% |
| Fuso Pharmaceutical Industries,Ltd. | 1.96 Billion JPY | -861.609% |
| Nippon Chemiphar Co., Ltd. | -494 Million JPY | 3923.077% |
| Tsumura & Co. | 20.01 Billion JPY | 5.655% |
| Kissei Pharmaceutical Co., Ltd. | 4.01 Billion JPY | -370.152% |
| Torii Pharmaceutical Co., Ltd. | 5.03 Billion JPY | -275.02% |
| Towa Pharmaceutical Co., Ltd. | 17.64 Billion JPY | -7.015% |
| Fuji Pharma Co., Ltd. | 3.85 Billion JPY | -389.528% |
| Zeria Pharmaceutical Co., Ltd. | 9.71 Billion JPY | -94.367% |
| KYORIN Holdings, Inc. | 6.01 Billion JPY | -214.086% |
| Taiko Pharmaceutical Co.,Ltd. | -3.07 Billion JPY | 713.381% |
| Daito Pharmaceutical Co.,Ltd. | 3.89 Billion JPY | -385.003% |
| SymBio Pharmaceuticals Limited | -811.66 Million JPY | 2426.813% |
| MedRx Co., Ltd | -933 Million JPY | 2124.223% |
| Mizuho Medy Co.,Ltd. | 5.15 Billion JPY | -266.577% |
| Solasia Pharma K.K. | -1.13 Billion JPY | 1758.121% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 896.878% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 6.5 Billion JPY | -190.554% |
| Cyfuse Biomedical K.K. | -697.43 Million JPY | 2807.915% |
| Toho Holdings Co., Ltd. | 19.33 Billion JPY | 2.302% |
| Koa Shoji Holdings Co.,Ltd. | 4.38 Billion JPY | -330.959% |